BioRestorative Therapies, Inc.

Third-quarter 2025 revenue was $11,800, entirely royalty revenue, versus $233,600 in Q3 2024, with the year-over-year decline attributed to timing of orders in the developing biocosmeceutical revenue stream. Loss from operations was $3.7 million, compared with $2.3 million a year ago. Net loss was $3 million, or $0.33 per share, versus a net loss of $1 million, or $0.13 per share, in Q3 2024. The company ended the quarter with $4.5 million of cash, cash equivalents and marketable securities and no outstanding debt, excluding about $1.1 million of gross proceeds from financing completed after quarter-end. Management did not provide formal next-quarter or full-year financial guidance, but said it expects to continue advancing BRTX-100 enrollment, pursue a December Type B FDA meeting, and build out biocosmeceuticals revenue with some near-term lumpiness.

Lance Alstodt framed the quarter as a positive inflection point operationally, saying the company is executing across both clinical and commercial efforts. He emphasized a “hybrid” model that pairs near-term revenue opportunities in biocosmeceuticals with longer-term clinical value, and said the business could become a very material contributor in 2026 and beyond. On BRTX-100, he said enrollment is nearing completion and that the pathway to a potential Phase III and BLA “has never been more visible,” while noting the company remains focused on careful resource management and cash efficiency.

Robert Eugene Kristal said Q3 revenue was $11,800, all from royalties, down from $233,600 in the prior-year quarter, and that the lower revenue reflected timing of orders in the biocosmeceutical stream. He reported a $3.7 million operating loss and a $3 million net loss, or $0.33 per share, versus a $1 million net loss, or $0.13 per share, last year. He also said the company finished the quarter with $4.5 million in cash, cash equivalents and marketable securities and no debt, before the roughly $1.1 million of gross proceeds from a post-quarter financing.

Analysts focused mainly on the size and commercialization path of the biocosmeceuticals business, how management would balance it with clinical development, and whether more Cartessa-like deals would be needed. Management said the opportunity is large, described it as a $63 billion market, and outlined a three-pronged approach: more distributors, direct sales into med spas/aestheticians, and possible direct-to-consumer products. On BRTX-100, management said enrollment is more than three-quarters complete, that the data will stay blinded for now, and that the December Type B meeting is intended to explore whether the company can move into a pivotal Phase III path without unblinding Phase II.